EGFR and cancer: Under these conditions, EGFR inhibitors like Erlotinib 22 and AG-1478 66 (Figure 2) are able to act as YAP/TAZ inhibitors and may be used for EGFR-driven cancers requiring YAP/TAZ transcription.